Introduction
Chronic migraine, defined by the International Classification of Headache Disorders as headache occurring on 15 or more days per month for more than three months with migraine features on at least 8 days, affects approximately 1 to 2 percent of the general population. A significant subset of chronic migraine patients -- estimated at 5 to 10 percent of those seen in specialty headache centers -- are refractory to conventional preventive therapies including beta-blockers, topiramate, valproate, CGRP monoclonal antibodies, and onabotulinumtoxinA. For these patients, low-dose ketamine has emerged as a mechanistically rational treatment option targeting the NMDA receptor-mediated central sensitization that drives migraine chronification.
NMDA Receptors in Migraine Pathophysiology
Cortical Spreading Depression
Cortical spreading depression (CSD), the electrophysiological event underlying migraine aura, involves a wave of neuronal depolarization that propagates across the cortical surface at approximately 3 to 5 mm per minute. NMDA receptor activation plays a central role in CSD initiation and propagation. Glutamate released during the depolarization wave activates NMDA receptors on adjacent neurons, facilitating the spread of the depolarization front. Preclinical studies have demonstrated that NMDA receptor antagonists, including ketamine, can suppress CSD frequency and amplitude in animal models (Kaube et al., 2000).
Trigeminovascular Sensitization
The trigeminovascular system -- comprising trigeminal sensory neurons that innervate cerebral blood vessels and meninges -- is the primary pain-generating pathway in migraine. Repeated activation of this system leads to peripheral and central sensitization, a process in which NMDA receptors in the trigeminal nucleus caudalis (TNC) and higher-order relay neurons become progressively more excitable. This central sensitization manifests clinically as allodynia (pain from normally non-painful stimuli such as light touch to the scalp), increased headache frequency, and reduced efficacy of acute treatments.
Info: In chronic migraine, NMDA receptor-mediated central sensitization in the trigeminal pain pathway creates a self-perpetuating cycle of heightened pain processing that conventional therapies often fail to interrupt. Ketamine's NMDA receptor blockade directly targets this mechanism.
Wind-Up and Long-Term Potentiation
At the cellular level, repeated nociceptive input to TNC neurons produces wind-up (progressive increase in neuronal firing to a constant stimulus) and long-term potentiation (sustained enhancement of synaptic efficacy). Both phenomena are NMDA receptor-dependent and are considered mechanisms by which episodic migraine transforms into chronic migraine. By blocking NMDA receptors, ketamine can interrupt wind-up and potentially reverse established long-term potentiation in pain circuits, providing a mechanistic basis for resetting the sensitized trigeminal system.
Clinical Evidence
Inpatient Multi-Day Infusion Protocols
The most robust clinical data for ketamine in chronic migraine come from inpatient multi-day infusion studies. Schwenk et al. (2018), in a retrospective review published in Regional Anesthesia and Pain Medicine, reported outcomes from 61 patients with refractory chronic migraine who received continuous intravenous ketamine infusions initiated at 0.1 mg/kg/hour and titrated to 0.75 mg/kg/hour over 3 to 7 days. Among patients who completed the infusion protocol, 75 percent experienced a reduction in headache intensity as measured by the numerical rating scale, with a mean reduction of 3.4 points on a 0-to-10 scale.
Lauritsen et al. (2016) described outcomes in 77 patients receiving multi-day inpatient ketamine infusions for refractory headache disorders, including chronic migraine and new daily persistent headache. Approximately 48 percent of patients reported at least a 50 percent reduction in headache severity at the time of hospital discharge. However, the durability of response was variable, with some patients experiencing sustained improvement over weeks to months and others reporting headache recurrence within days of infusion completion.
Outpatient Infusion Series
Clinical: Outpatient ketamine infusion protocols for chronic migraine typically employ lower doses (0.5 mg/kg over 40 to 60 minutes) administered in serial sessions, though the evidence base for this approach is limited to case series and small observational studies.
Outpatient ketamine infusions, administered at standard subanesthetic doses of 0.5 mg/kg over 40 minutes in series of 4 to 6 infusions, have been reported in case series with variable results. Pomeroy et al. (2017) described a series of refractory migraine patients treated with outpatient ketamine infusions, with approximately half reporting clinically meaningful improvement in headache frequency or severity. The lower total ketamine exposure in outpatient protocols compared to multi-day inpatient infusions may explain the generally lower response rates observed in outpatient settings.
Intranasal Ketamine for Migraine Aura
A distinct application of ketamine in migraine involves intranasal administration during the aura phase to prevent headache progression. Afridi et al. (2013) investigated intranasal ketamine (25 mg) for treatment of migraine aura in a double-blind, placebo-controlled crossover study. Ketamine significantly reduced the severity of aura symptoms compared to placebo, consistent with its ability to suppress cortical spreading depression. However, the effect on subsequent headache severity was inconsistent, and the practical utility of this approach is limited by the unpredictable timing of aura onset.
Patient Selection
Ketamine for chronic migraine should be reserved for patients who meet the following general criteria: a confirmed diagnosis of chronic migraine by International Classification of Headache Disorders criteria; failure of or intolerance to at least three classes of conventional preventive therapies; absence of medication overuse headache (or successful withdrawal from overused medications); and adequate evaluation to exclude secondary headache disorders.
Patients should be screened for cardiovascular risk factors, given ketamine's sympathomimetic effects, and for a history of substance use disorders or psychotic spectrum conditions. The presence of cutaneous allodynia, a clinical marker of central sensitization, may identify patients who are particularly likely to respond to NMDA receptor-targeted therapy, though this hypothesis has not been prospectively validated.
Infusion Protocols
Inpatient Protocol
Inpatient multi-day infusion protocols represent the most studied approach. The typical protocol involves hospital admission to a monitored unit with continuous telemetry, initiation of ketamine at 0.1 mg/kg/hour, gradual titration over 24 to 48 hours to a target rate of 0.3 to 0.75 mg/kg/hour based on tolerability, continuous infusion for 3 to 7 days, and concurrent administration of antiemetics (ondansetron) and anxiolytics as needed. Vital signs are monitored continuously, with particular attention to blood pressure and heart rate. Liver function tests and urinalysis should be obtained at baseline and monitored during extended infusions.
Outpatient Protocol
For outpatient treatment, standard subanesthetic infusions of 0.5 mg/kg over 40 minutes administered two to three times weekly for two to three weeks represent a common approach, extrapolated from depression treatment protocols. Post-infusion monitoring for 60 to 90 minutes is standard, and patients should not drive for 24 hours following treatment.
Safety Considerations
The safety profile of ketamine in migraine patients is generally consistent with that observed in other clinical populations. Transient blood pressure elevation, dissociation, nausea, and dizziness are the most commonly reported adverse effects. Extended inpatient infusions carry additional considerations, including hepatotoxicity monitoring (liver enzyme elevation has been reported with prolonged infusions) and urological surveillance, given the known association between chronic high-dose ketamine use and lower urinary tract symptoms.
Patients with migraine may be at particular risk for ketamine-induced nausea and vomiting, given the overlap between migraine nausea mechanisms and ketamine-triggered emesis. Prophylactic antiemetic administration should be considered routine in this population.
References
- PubMed: Ketamine Infusion for Refractory Headache: A Retrospective Analysis of 77 Patients — Retrospective study of inpatient ketamine infusions for refractory chronic migraine and daily persistent headache
- PubMed: Ketamine for Chronic Migraine: A Systematic Review — Systematic review evaluating the evidence base for ketamine in chronic and refractory migraine
- PubMed: NMDA Receptor Blockade and Cortical Spreading Depression — Preclinical study demonstrating NMDA receptor involvement in cortical spreading depression relevant to migraine aura
- NIH: Migraine Information Page — National Institute of Neurological Disorders and Stroke resource on migraine pathophysiology and treatment
Share